Author

Alise Nacson

Observed names: A Nacson, A. Nacson, Alise B. Nacson, Nacson, Alise

Institution: Sarepta Therapeutics (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), IQVIA (United Kingdom), Brod Group, Sarepta Therapeutics (United States)

ORCID: 0009-0004-9532-4274

Observed ORCID: 0009-0004-9532-4274

OpenAlex ID: A5089880100

Measuring cough severity: Perspectives from the literature and from patients with chronic cough

2009 · Margaret Vernon, Nancy Leidy, et al. · Cough · 71

Measuring cough severity: development and pilot testing of a new seven-item cough severity patient-reported outcome measure

2010 · Margaret Vernon, Nancy Kline Leidy, et al. · Therapeutic Advances in Respiratory Disease · 62

Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome

2025 · J. Scott Andrews, Drishti Shah, et al. · Journal of Patient-Reported Outcomes · 7

Measuring Cough Severity: Perspectives From the Literature and Patients With Chronic Cough

2008 · Margaret K. Vernon, Linda M. Nelsen, et al. · CHEST Journal · 6

Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial

2025 · Ivana Audhya, Alise B. Nacson, et al. · Neurology and Therapy · 2

Cognitive debrief of the Clinical Global Impression of Improvement for Nonseizure Symptoms measure in Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS): The Caregiver Perspective (P14-1.002)

2023 · Drishti Shah, Scott Andrews, et al. · Neurology · 2

Pcr130 a Qualitative Study to Explore Patient Perspectives on Future Gene Therapy for Limb Girdle Muscular Dystrophy (lgmd) Sarcoglycanopathy Subtypes 2e/r4, 2d/r3, and 2c/r5

2026 · Ivana Filipovic Audhya, Alise Nacson, et al. · Value in Health

PCR45 Cognitive Debrief of the PROMIS Parent Proxy Mobility Item Bank in Caregivers of Children Living With Duchenne Muscular Dystrophy

2025 · Chloe Carmichael, Ania Filus, et al. · Value in Health

EE357 Estimating Health State Utilities in LGMD 2E/R4, 2D/R3, and 2C/R5: Analysis of EQ-5D Baseline Data From the JOURNEY Natural History Study

2024 · A Nacson, P Fromy, et al. · Value in Health

PCR220 Patient-Reported Outcomes in LGMD 2E/R4, 2D/R3 and 2C/R5: Descriptive Analysis of Baseline PROMIS Data From the JOURNEY Natural History Study

2024 · I. Filipovic Audhya, A. Nacson, et al. · Value in Health

Trends in COA Use and Regulatory Acceptance for Epileptic Encephalopathy and Developmental Epileptic Encephalopathy Indications (P13-1.006)

2023 · Christina Graham, Michael Chladek, et al. · Neurology

Disease and Treatment Burden in Children and Adolescents with Growth Hormone Deficiency

2015 · Meryl Brod, Lise Højbjerre, et al. · 54th ESPE Meeting (ESPE 2015)

Growth Hormone deficiency in Pediatrics: Concept Elicitation To Support The Development of Child Pro And Parent Obsro Measures

2015 · M. Brod, J. Håkan-Bloch, et al. · Value in Health

Works count: 15

Citation count: 150

H-index: 4

I10-index: 2